McIlrath & Eck’s Sarepta Therapeutics SRPT Stock Holding History

McIlrath & Eck’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5	Closed	-$689	–	938
2023 Q1	$689	Buy	+5	New	+$649	﹤0.01%	862
2021 Q2	–	Sell	-7	Closed	-$1K	–	830
2021 Q1	$1K	Hold	7	–	–	﹤0.01%	732
2020 Q4	$1K	Hold	7	–	–	﹤0.01%	665
2020 Q3	$1K	Hold	7	–	–	﹤0.01%	645
2020 Q2	$1K	Hold	7	–	–	﹤0.01%	643
2020 Q1	$1K	Hold	7	–	–	﹤0.01%	637
2019 Q4	$1K	Hold	7	–	–	﹤0.01%	618
2019 Q3	$1K	Sell	7 -78	-92%	-$9.21K	﹤0.01%	606
2019 Q2	$10K	Hold	85	–	–	0.01%	342
2019 Q1	$10K	Buy	+85	New	+$10.9K	0.01%	342

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

McIlrath & Eck's SRPT Position: Q2 2023 in Review

McIlrath & Eck sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 5 shares — an estimated $689 sold.

McIlrath & Eck first reported a position in SRPT in Q1 2019 and held it in 10 quarters. The position peaked at $10K in Q2 2019. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

McIlrath & Eck reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
McIlrath & Eck sold 5 Sarepta Therapeutics shares in Q2 2023, an estimated $689.
McIlrath & Eck first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 10 quarters.
McIlrath & Eck's Sarepta Therapeutics position peaked at $10K in Q2 2019.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on McIlrath & Eck's 13F filing for Q2 2023, filed 7 Aug 2023.